drugset / Trial / NCT01129232

Diabetes Virus Detection Project, Intervention With GAD-alum

NCT01129232

Phase 2 Terminated 6 enrolled Oslo University Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purposes of this study are to test whether GAD vaccination can stop the progression of newly diagnosed type 1 diabetes, to describe the related immunological processes (insulitis) in pancreas and small intestines evolving the mechanism of the effect of GAD vaccination and finally try to detect viruses and virus receptors directly in the insulin producing beta cells of the pancreas in patients with newly diagnosed type-1 diabetes mellitus (T1D).

Timeline

Start
2011-01
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GAD-Alum Vaccine 20 ug Subcutaneous